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ABSTRACT
Metastasis accounts for the poor prognosis of the majority of solid
tumors. The phenotypic transition of nonmotile epithelial tumor cells to
migratory and invasive ‘‘mesenchymal’’ cells (epithelial-to-mesenchymal
transition [EMT]) enables the transit of cancer cells from the primary
tumor to distant sites. There is no single marker of EMT; rather, multiple
measures are required to define cell state. Thus, the multiparametric
capability of high-content screening is ideally suited for the comprehen-
sive analysis of EMT regulators. The aim of this study was to generate a
platform to systematically identify functional modulators of tumor cell
plasticity using the bladder cancer cell line TSU-Pr1-B1 as a model system.
A platform enabling the quantification of key EMT characteristics, cell
morphology and mesenchymal intermediate filament vimentin, was de-
veloped using the fluorescent whole-cell-tracking reagent CMFDA and a
fluorescent promoter reporter construct, respectively. The functional effect
of genome-wide modulation of protein-coding genes and miRNAs coupled
with those of a collection of small-molecule kinase inhibitors on EMT was
assessed using the Target Activation Bioapplication integrated in the
Cellomics ArrayScan platform. Data from each of the three screens were
integrated to identify a cohort of targets that were subsequently examined
in a validation assay using siRNA duplexes. Identification of established
regulators of EMT supports the utility of this screening approach and
indicated capacity to identify novel regulators of this plasticity program.
Pathway analysis coupled with interrogation of cancer-related expression
profile databases and other EMT-related screens provided key evidence to
prioritize further experimental investigation into the molecular regulators
of EMT in cancer cells.
INTRODUCTION
A
major concern in cancer is the metastasis of tumor cells
to distant organs, as this accounts for the majority of
treatment-refractory cancers and the poor prognosis of
the disease. Indeed, metastasis is responsible for *90%
of cancer deaths.1 Epithelial-to-mesenchymal transition (EMT), where
there is loss of epithelial differentiation and acquisition of a more
mesenchymal phenotype, endows tumor cells with migratory and in-
vasive capabilities that enable spread to distant sites. The reverse pro-
cess, mesenchymal-to-epithelial transition (MET), is implicated in
secondary tumor growth where the mesenchymal-like cells readopt
epithelial properties to enable colonization at secondary sites.2,3
While there is no single unique marker of EMT/MET,4 EMT is
typically characterized by the loss of the epithelial cell–cell adhesion
molecule E-cadherin and the presence of the mesenchymal interme-
diate filament protein vimentin.2,3 Apart from this phenotypic switch,
the cells transform from their epithelial cobblestone-like appearance
with apicobasal polarity to an elongated and more variable shape.
Most of the studies on EMT modulators have focused on one or two
pathways to decipher the functions of a given gene and typically use
single-parameter assays. High-throughput, high-content screening
(HCS) provides a discovery approach that allows multiple cellular
parameters to be quantified in a single well enabling a complex bi-
ological process to be better understood. To identify modulators of
EMT/MET, a multiparametric HCS assay using the TSU-Pr1-B1
bladder cancer cell line5 was developed using a fluorescent promoter
reporter construct based on vimentin and cell morphology. A CMFDA
fluorescent whole-cell mask was used to label cells at the end of the
experiment to enable cell segmentation and quantitation of cell shape.
We report a multiparametric high-content screen of genome-wide
protein-coding siRNA, microRNA, and small-molecule kinase inhibitor
libraries to modulate tumor cell epithelial/mesenchymal state in TSU-
Pr1-B1metastatic bladder cancer cells. Multiple phenotypic parameters
enable several distinct binning classes to finely dissect EMT. Using a
defined analysis pathway, the data obtained using the 3 libraries were
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integrated and used to provide ad-
ditional evidence to rank hits, with
the goal of minimizing the gener-
ation of false positive and false
negative results that can occur in
RNAi-based screening. Validated
hits were subsequently assessed
for potential biological significance
using gene ontology pathway
analysis and association with clin-
ical cancer phenotypes to provide
further information regarding their
potential role in EMT/MET.
MATERIALS AND
METHODS
Cell Culture
All bacterial culturework utilized
the DH5alpha strain of Escherichia
coli in either 25g/L Difco LB
Broth, Miller or 40g/L Difco LB
Agar, Miller (Becton Dickinson)
and where required supplemented
with 100mg/mL of carbenicillin or
30mg/mL of kanamycin.
TSU-Pr1-B1 cells were main-
tained in Dulbecco-modified Ea-
gle’s medium (DMEM), containing
5% fetal bovine serum (FBS), L-
glutamine, and 4.5 g/L D-glucose
(Gibco).5 Cells were routinely
passaged at 7.5 ·105 cells per T75
flask (Greiner) using 0.25% trypsin
in EDTA. Frozen stocks were stored
at 2 ·106 cells per vial in 10%
DMSO/20% FBS/DMEM.
Generation of Fluorescent
Protein Reporter Constructs
and Clonal Cell Lines
Vimentin fluorescent reporter construct was generated by repla-
cing the CMV promoter using NdeI and SalI sites of the pDsRed2-N1
vector (Clontech) with the vimentin promoter sequences (Fig. 1A;
Supplementary Materials and Methods; Supplementary Fig. S1;
Supplementary Data are available online at www.liebertpub.com/
adt). A similar strategy was used to generate E-cadherin promoter
reporter constructs (Supplementary Materials and Methods).
Stable transfectants were cloned individually by limiting dilution
(Supplementary Materials and Methods). Cell suspensions (100 mL)
were aliquoted into 96-well plates at a concentration of 0.5 cells/well,
3 cells/well, and 10 cells/well. The presence of a single cell per well
was verified by microscopy and monitored for proliferation. Viable
clones were expanded and the presence of the fluorescent vector
was confirmed using the Arrayscan VTi high-content microscope
(Cellomics) and FACS sorted (MoFlo Flow Cytometer machine;
Beckman Coulter) based on dsRed expression.
High-Content Screen
Cell lines were maintained in culture medium as described previ-
ously, supplemented with 800 mg/mL geneticin (Life Technologies).
Cells were resuscitated from the cell bank (passage number 46, 2 · 106
cells per vial), and passaged twice (seeded at 7.5 · 105 cells per T75
flask at each passage every 3 days) prior to each experiment. The
same serum batch (Life Technologies) was used for the entire screen.
The HCS protocol is summarized in Table 1. A Biotek 406 liquid
dispenser/plate washer (BioTek) was used to dispense cells, change
Fig. 1. Development of the reporter and screen imaging. (A) Schematic representation of the human
vimentin promoter, including the regulatory elements, that was generated by PCR and cloned up-
stream into reporter vector dsRed. NE, negative element; AP1, AP1 binding site; NF-kB, NF-kB binding
site. Arrow indicates transcription-initiation site. (B) Three channels were used in the screening assay
to capture modulation of the EMT phenotype: CMFDA staining, vimentin/dsRed channel, and DAPI
nuclear stain. The blue lines around the cells represent the individual cell mask based on the cyto-
plasmic masking of CMFDA channel (Channel 1) according to bioapplication algorithm settings. Scale
bar= 100 mM. (C) The morphological phenotype associated with mock and positive control siSEMA3A
as seen in the CMFDA channel. The percentage of responders of LWR for mock cells is 5% compared
with 20% for SEMA3A-knockdown cells, demonstrating that siSEMA3A cells are more elongated than
mock cells. Scale bar = 100 mM. CFMDA, 5-chloromethylfluorescein diacetate; DAPI, 40,6-diamidino-2-
phenylindole; EMT, epithelial-to-mesenchymal transition; LWR, length width ratio.
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media, add transfection reagent, and fix and
stain cells. The z-height was set at a conser-
vative level of 42 for all aspirating steps,
leaving 15mL residual volume. A Caliper
Sciclone ALH3000 (Caliper LifeSciencesA)
liquid-handling robot was used to deliver the
siRNA to the lipid for complexing.
Black-walled, clear-bottom plates (384
wells; Corning 3712) were used for all HCS.
Lipofectamine RNAiMax (Life Technolo-
gies) was used for all siRNA and miRNA
transfections at 0.06 mL per well. All siRNA
and miRNA reagents (Dharmacon RNAi
Technologies) were hydrated in 1· siRNA
resuspension buffer and transfected in du-
plicate at a final concentration of 40nM for
the SMARTpool primary screen, 25 nM for
the individual siRNA duplex secondary vali-
dation screen, and 25nM for the miRNA
screens. Reagents were complexed with lip-
id:Opti-MEM for 20min at room tempera-
ture before the addition of 1,200 cells per
well in geneticin-free media. Media were
changed at 24 h post-transfection and the as-
say was completed at 72h post-transfection.
For the siRNA and miRNA screens, mock
transfection (lipid only, 16 wells) was used as
the negative control and siSEMA3A SMART-
pool (M-020091-01, 6 wells) was used as a
positive control for morphology. siGENOME
nontargeting control SMARTpool #1 (catalog
number D-001206-13; Dharmacon) was also
trialed as a negative control, but variable
phenotypic effects were observed that were
inconsistent with lipid-only transfection and
other protein-coding targets that did not
cause a functional effect. We considered
it most likely that this control was causing
off-target effects in our specific cell line
that coupled with the sensitive assay read-
out was resulting in phenotypic changes,
and therefore chose to normalize all data
to the lipid-only control. The Dharmacon
SMARTpool protein-coding genome (18,120
targets, RefSeq57, catalogue numbers: G-
003505, G-003605, G-003705, G-003805,
G-004655, G-005005, G-005105, G-005615,
G-005625, and G-005635; Dharmacon) and
miRNA mimic (1,239 targets, miRBase16,
catalogue number C-300879-01; Dharma-
con) and inhibitor (1,224 targets, miRBase16,
catalog number IH-300707-08; Dharmacon)
collections were used for screening. The
Table 1. High-Content Screening Assay Protocol Table
Step Parameter Value Description
1a For siRNA/miRNA
Lipid/DMEM dispensing 0.06 mL lipid in 12.5mL DMEM 5-min complexing
For kinase inhibitors
Drug/media dispensing 12.5mL 0.01 to 10mM in 0.2% DMSO
1b For siRNA/miRNA
siRNA/miRNA addition 40 nM siRNA, 25 nM miRNA Controls: mock, siSEMA3A
1c For siRNA/miRNA
Incubation time 20min Room temperature
2 Plate cells 25 mL 1200 TSU-Pr1-B1 cells
3 Incubation 24 h 37C with 5% CO2
4 Media change 40 mL 24 h post-transfection
5 Cell cytoplasmic staining 40 mL CMFDA 1mM
72 h post-transfection of siRNA/miRNA
48 h post-treatment with kinase inhibitors
6 Incubation time 30min 37C, 5% CO2
7 Media change 40 mL Replace dye media with fresh media
8 Incubation time 30min 37C, 5% CO2
9 Cell fixing 25 mL 4% paraformaldehyde in PBS
10 Incubation time 10min Room temperature
11 Cell nuclear staining 25 mL DAPI 1 mg/mL
12 Incubation time 20min Room temperature
13 Storage 50 mL PBS
14 Assay readout 402, 488, and 558 nm Cellomics ArrayScan imaging
Step Notes
For siRNA/miRNA:
1a. siRNA/miRNA screening was performed in duplicate using 384-well, black-walled, clear-bottom plates
(Corning 3712). The lipid/DMEM mixture was dispensed using the Biotek platform in a tissue culture hood.
1b. siRNA addition was performed using the Caliper liquid-handling robot. Controls were preplated at final
concentration. For siRNA and miRNA, controls are in the following positions: mock in wells A02, B02, F02,
G02, J02, N02, O02, P02, A23, B23, C23, E23, I23, K23, O23, P23; siSEMA3A in wells D02, I02, K02, F23, L23,
N23; Columns 1 and 24 were left empty.
1c. Plates were incubated at room temperature.
For kinase inhibitors:
1a. Each compound was used at 11 concentrations in 384-well, black-walled, clear-bottom plates (Corning
3712). Medium containing the drugs was prepared at Walter and Eliza Hall Institute of Medical Research
before transportation to the Victorian Centre for Functional Genomics (VCFG) for cell dispensing. For
kinase inhibitor screening, columns 1–11 or 12–22 contain 11 point concentrations of each compound.
Controls are in the following positions: siSEMA3A in wells F23, G23, H23, J23, L23, M23, and N23; column
24 was mock treatment.
2. Cell plating was using the Biotek instrument in geneticin-free media.
(continued)
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siRNA and miRNA screens were performed using duplicate plates.
The top 400 gene targets, binned as hits based on multiple data
integration (see ‘‘Integration of siRNA, miRNA, and Kinase In-
hibitor Libraries’’ section), were cherry picked as individual siRNA
duplexes into 384-well plates with additional transfection con-
trols (mock transfection, siSEMA3A as well as siCDH22 [catalog
number M-013099-00-0005; Dharmacon], which was identified
during primary screening as a positive control for vimentin/dsRed
reporter intensity) and edges were excluded. Duplexes were
transfected at a final concentration of 25 nM each and the pro-
cedure was followed as per the primary screen.
At 72 h post-transfection, media were removed using the Biotek 406
and cells were stained with 5-chloromethylfluorescein diacetate (Cell-
Tracker Green CMFDA; Life Technologies) at a final concentration
of 1 mM in serum-free medium. After 30-min incubation at 37C,
the dye was removed and replaced with fresh, prewarmed serum-
containing medium and incubated for 30min. Cells were then fixed
in 25 mL of 4% paraformaldehyde (Sigma-Aldrich) in phosphate-
buffered saline (PBS) for 10min, followed by nuclear staining with
40,6-diamidino-2-phenylindole (DAPI; 25 mL of 1mg/mL stock) for
20min at room temperature. DAPI was replaced with 50 mL PBS,
plates were sealed with foil covers, and cells were imaged at room
temperature as described below.
The small-molecule kinase inhibitor library consisted of 131
commercially available kinase inhibitors (Supplementary Table S1;
SYNthesis Med Chem Pty Ltd). Each compound was dissolved in
DMSO and, diluted in culture media, added directly to assay plates
before cell dispensing (1,200 cells in 25 mL DMEM per well). Com-
poundswere screened at 11 distinct concentrations ranging from 0.01
to 10 mM in 384-well-plate format. DMSO-only treatment (0.2%) was
used as the negative control. Following a 48-h incubation, the ex-
periment was concluded as per the siRNA/miRNA screens.
Image Acquisition and Analysis
A fully automated Cellomics Arrayscan
VT1 high-throughput microscope equipped
with Cellomics Bioapplication software
(Cellomics; Thermo Fisher) with a 20 · ob-
jective was used to identify 1,000 cells from
25 fields per well. Images were acquired in
three channels: Channel 1 for cytoplasmic
CMFDA (XF93-FITC filter), Channel 2 for
nuclear DAPI (XF93 Hoechst filter), and
Channel 3 for the vimentin/dsRed reporter
channel (XF93-TRITC filter). The Target
Activation V3 Bioapplication was used for
analysis. Cell segmentation occurred in the
CMFDA channel followed by identification
of nuclei in the DAPI channel and quanti-
tation of vimentin promoter expression in
the dsRed channel (Fig. 1B). A responder
was defined as having cells whose cell
shape and/or vimentin/dsRed reporter in-
tensity level was greater than the 95th
percentile of the mock transfected population of cells. The
threshold was determined by evaluation of 4 mock transfection
reference wells included in the same positions on each independent
plate. This calculation is one of the predefined settings in the Cellomics
bioapplication and uses the operator-designated reference (here mock
wells) to identify the interventions that produce a response beyond two
standard deviation away from the mean of the reference population.
The outputs recordedwere as follows: cell health (SelectedObjectCount,
ValidFieldCount, and SelectedObjectCountPerValidField), percent-
age of responder of cells above the reference-well-defined aver-
age object length width ratio (LWR) to measure morphological
change (%RESPONDER_ObjectShapeLWRCh1), and percentage of
responder of cells above the reference-well-defined average in-
tensity to measure reporter activity (%RESPONDER_TotalIntenCh3
and %RESPONDER_AvgIntenCh3).
Screen metrics reported the Z0 factor for the %RESPONDER_
ObjectShapeLWRCh1 readout between the positive (siSEMA3A) and
negative (mock) controls. The average, standard deviation, and %
coefficient of variation (%CV) were reported for all controls to
measure reproducibility. Plate-specific metrics included analysis of
replicate correlation (Pearson and Spearman correlation coeffi-
cients), whole-screen scatter plots, and normal Q-Q plots. siRNAs/
miRNAs with cytotoxic effects were identified by a low cell count
(<500 cells in 25 fields) and were removed from further analysis and
calculation of the robust z-score. The formula used for robust z-
score was
Robust z-score =
sample value - sample median
sample median absolute deviation
Four hundred siRNA targets were selected for validation via
deconvolution of the SMARTpools into their constituent siRNAs
and rescreening using the same technical parameters described
Table 1. (Continued)
3. The plates were gently centrifuged at low speed (pulse-centrifuge to 500g) before incubation.
4. Complete growth media change (DMEM containing 5% fetal bovine serum) was performed using the Biotek
platform in a tissue culture hood.
5. Media were removed using the Biotek platform and cells were stained with 5-chloromethylfluorescein
diacetate (CellTracker Green CMFDA; Invitrogen). The lyophilized CMFDA was dissolved in high-quality
dimethyl sulfoxide (DMSO) to a 1mM stock solution and then diluted to a final working concentration of
1 mM in serum-free medium and prewarmed to 37C prior to adding to plates.
6. Plates were incubated at 37C.
7. The dye working solution was replaced with fresh, prewarmed medium with serum.
8. Plates were incubated at 37C.
9. Media were removed and freshly made 4% paraformaldehyde in PBS was added using the Biotek platform.
10. Plates were incubated at room temperature.
11. The fixation buffer was removed. DAPI was diluted in DMEM (1:1,000 dilutions for 1mg/mL final
concentration) and added to wells.
12. Plates were wrapped in aluminum foil to protect from light and incubated at room temperature.
13. Plates were sealed using an aluminum foil heat sealer (Velocity 11).
14. The imaging channels used were XF93-Hoechst (402 nm), XF93-FITC (488 nm), and XF83-TRITC (558 nm);
0.06 s, 0.005 s, and 0.46 s exposure.
DAPI, 40 ,6-diamidino-2-phenylindole; DMEM, Dulbecco-modified Eagle’s medium; PBS, phosphate-buffered saline.
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earlier. The validation screen met all standard quality-control pa-
rameters. Given these targets were theoretically hits, the robust
z-score strategy for analysis could not be applied and therefore fold
change relative to mock was used. Wells that scored cell viability of
< 0.5-fold change to mock were excluded from further analysis. The
threshold cutoff for the LWRmesenchymal (LWRM) bin was defined
as 13.5, which was three-fold the average of the LWR mock control
value (mean = 4.53, standard deviation = 0.7). The threshold for the
vimentin/dsRed reporter intensity readout was set at 22.16, which
represented 20% of the minimum value in the primary 400 hits for
vimentin and was calculated based on the intensity values associ-
ated with the revised z-score of ‡ 4 used to take candidates through
from the primary screen. Any gene that scored at least 2 of 4 siRNA
duplexes recapitulating the SMARTpool phenotype was defined as
a high-confidence-validated target.
Data Mining of Hits
Enrichment analysis to identify significant pathways and process
networks associated with the gene set of interest was performed
using Metacore (http://thomsonreuters.com/metacore/; Thomson
Reuters). The significance level for the false discovery rate filter was
set to 0.05. The validated gene set was also analyzed against other
cancer-related gene expression data from Oncomine database
(www.oncomine.org) using a P value of 0.01 and odds ratio of 2.0
as the threshold.
RESULTS
Promoter Reporter
To utilize the vimentin promoter as a mesenchymal reporter, the
human vimentin promoter sequence was isolated, a serial deletion
was generated, and constructs were assessed for activity by mea-
suring luciferase activity in transiently transfected TSU-Pr1-B1 cells
(Supplementary Fig. S1). The construct with the highest reporter
activity (V1) was then transferred to a fluorescent reporter con-
struct and stably transfected TSU-Pr1-B1 clones were generated. E-
cadherin promoter reporter constructs were assessed using the same
strategy, but as they did not generate a strong robust signal in the
TSU-Pr1-B1 cell system they were not further developed as a measure
for HCS (Supplementary Fig. S2).
SMARTpool Protein-Coding Library Screen
Transfection and HCS assay optimization were established for the
TSU-Pr1-B1 cells using the mock transfection together with siSE-
MA3A as a positive control. In comparison to controls, knockdown
of SEMA3A produced a significant increase in morphological change
as measured by the LWR (20% responders for experimental siSE-
MA3A and 17% for siSEMA3A-transfected positive controls com-
pared with 5% for mock transfected cells) without any effect on
vimentin reporter intensity (Fig. 1C).
We observed an overall cell death rate of*10% of targets in this
screen (defining death as a fold change of < 0.5 relative to mock
wells). A number of the targets that when knocked down signifi-
cantly reduced cell viability belonged to overlapping gene ontology
categories of mRNA processing (P = 7.6 · 10 - 12, 48 genes in data
of 160), mitosis (P = 7.6 · 10 - 6, 38 genes), spindle microtubules
(P = 7.6 · 10 - 5, 25 genes), regulation of cytoskeleton rearrange-
ment (P = 7.6 · 10 - 5, 36 genes), cell cycle G2M (P = 4.2 · 10 - 5, 40
genes), and translation initiation (P = 1.0 · 10 - 3, 31 genes). Targets
that caused cell death were excluded from the robust z-score
analysis to reduce false positives.
For binning and hit identification for the siRNA and miRNA
screens, the samples on each plate were normalized to the aver-
age mock control wells and the robust z-score was calculated on
the normalized samples for both the %RESPONDER_Object-
ShapeLWRCh1 and the %RESPONDER_TotalIntenCh3 readouts on a
per plate basis (sample-based normalization). The duplicate plates
were averaged and a robust z-score was calculated across all the
library plates. Samples with disparate values between replicates
( > 25% difference between the A and B plate values) were excluded
from further analysis. Robust z-score cutoffs of £ - 2 or ‡ 2 were
used to identify an initial hit list. Since this assay involves two key
parameters, LWR and reporter activity, the binning was designed to
capture both double-positive and single-positive hits (Table 2).
For LWR, a robust z-score of > 2 was assigned as LWRM (i.e., the
cells are shifting to a mesenchymal-like phenotype), while a robust z-
score of <- 2 was assigned LWR epithelial (LWRE) (shifting toward a
more epithelial-like phenotype). Likewise for vimentin/dsRed reporter
activity, a robust z-score of >2 was assigned as VHM (vimentin pro-
moter dsRED reporter activity associatedwith increasedmesenchymal-
like properties) and <- 2 assigned as VHE (vimentin promoter dsRED
reporter activity associated with increased epithelial-like properties).
Applying a robust z-score cutoff of ‡2 there was a 17% hit rate across
the primary siRNA SMARTpool screen. The breakdown of hits and
representative images are shown in Table 2 and Figure 2.
miRNA Library Screens
The miRNA mimic and inhibitor screens (both performed as single-
pass screens with no subsequent validation) were performed using the
same technical conditions as the siRNA screen. Consistent with the
literature6 and our experience in the Victorian Centre for Functional
Genomics (K. Simpson), the mimics were far more bioactive than the
inhibitors, with a death rate of 27% compared with 0.44%. There were
22 double-bin hits identified using the miRNA mimic library and 3
from the miRNA inhibitor library. In the miRNA inhibitor screen, a
subset of 18 miRNAs were binned as LWRE (having LWR z-score of
less than - 2), which indicates they are causing the cells to shift
toward a more epithelial-like phenotype. These miRNAs did not
affect reporter activity compared with mock control. An overview
of the miRNA screens and representative images is shown in Table 3
and Figure 3.
Kinase Inhibitor Library Screen
To assess the effects of kinase inhibitors on EMT characteristics,
the LWR and vimentin/dsRed total intensity graph profiles were
evaluated against the object count and object per field graphs.
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Compounds (46) that caused a significant drop in cell count to
< 500 cells (at any concentration) were excluded from further
analysis. Of the 131 compounds, 25 showed significant effects on
the assay outputs. The overall outcome of kinase inhibitor screen
and representative graph profiles of
one of the LWRE hits are shown in
Table 4 and Figure 4.
Integration of siRNA, miRNA,
and Kinase Inhibitor Libraries
The primary hit bins from each
screening strategy were integrated to
prioritize a list of targets for detailed
validation. Due to the large number of
hits identified at a z-score of 2 in the
siRNA screen, we refined the target
list by applying more stringent robust
z-score cutoffs. All double-bin hits
(LWRM and VHM) with LWRM z-
score ‡ 3 or VHM z-score ‡4 were
included. For single-bin hits, a higher
z-score cutoff was applied with an
LWRM z-score of ‡ 5 or VHM z-score
of ‡ 6. This resulted in 279 hits.
Putative miRNA target genes of miRNA
mimic and inhibitors that produced a z-
score of £ - 2 or ‡2 were identified using
the miRanda database (August 2010 re-
lease; www.microRNA.org; mirSVR score
of £ - 0.17) and used as an additional line
of evidence to add weight to the targets
identified in the siRNA screen. This resulted
in targets identified in the siRNA screen
with LWRM z-score ‡ 4 or VHM z-score ‡ 5
also being included in the validation round
if they also were a predicted miRNA target
gene.
From the kinase inhibitor screen, the ma-
jor kinases targeted in the kinase inhibitor
screen were compared with kinases identi-
fied in the revised siRNA bins described
previously. Twenty-five compounds, target-
ing 15 protein kinases, were identified as hits
(Fig. 4A). Of these kinases, 7 scored LWRMor
VHM in both the siRNA and kinase inhibitor
screens and 8 scored no change (NC) in the
siRNA screen but were binned as hits to be
included in secondary validation screening
due to robust responses in the compound
screen.
Secondary Validation Screening
Taking these three screens together
and the revised binning strategies, we derived a list of 400 genes
to progress to validate via deconvolution of the SMARTpool into
its constituent siRNAs. Nine targets were included that scored NC
(8) or low count (1) in the siRNAscreen due to the robust effects
Table 2. Overview of siRNA Screen
Binning
Class
Primary
Screen Hits
(z-score‡2
or£- 2)
Primary
siRNA Screen
Revised z-scorea
Secondary
Screen
Candidatesb
Secondary
Screen Results
(Number of Duplexes:
Number of Targets)
LWRM and
VHM
350 All double-bin hits with
192 LWRM ‡ 3 or VHM ‡ 4
192 3/4: 3
2/4: 39
LWRM only 1003 LWRM ‡ 5 31 80 3/4: 5
2/4: 35
VHM only 1738 VHM ‡ 6 56 119 4/4: 4
3/4: 40
2/4: 109
LWRE only 0 None 0 0
VHE only 0 None 0 0
NC 12999 None 8 £ 1/4: 179
LC 2085 None 1 0
aRevised z-scores. LWRM and VHM: LWRM z-score ‡ 3 or VHM z-score ‡ 4; LWRM z-score ‡ 5; VHM z-score ‡ 6.
bAssembled from integrated analysis of siRNA, miRNA, and kinase inhibitor library screens.
LC, low cell count; LWRE, length width ratio epithelial; LWRM, length width ratio mesenchymal; NC, no
change; VHE, vimentin promoter dsRED reporter activity associated with increased epithelial-like properties;
VHM, vimentin promoter dsRED reporter activity associated with increased mesenchymal-like properties.
Fig. 2. Overview of primary siRNA screen. Representative images from each binning class at 72h
post-transfection. siRAP2C represents the double-positive LWRM/VHM bin with an LWR z-score of
7.03 and vim/dsRed z-score of 2.99. siCCNL1 is classified in the LWRM-only bin with a z-score of 5.32.
siIGFBP7 is in the VHM-only bin with a z-score of 6.63. RAP2C, member of RAS oncogene family;
CCNL1, cyclin L1; IGFBP7, insulin-like growth factor binding protein 7. Scale bar= 100mM. Images are
a merge of CMFDA (green) and dsRED (red) channels. LWRM, length width ratio mesenchymal; VHM,
vimentin promoter dsRED reporter activity associated with increased mesenchymal-like properties.
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of compounds targeting these genes in the compound screen.
The screen was repeated with this target list and quantitated as
described previously. A target was classified as validated if two
or more of the four individual siRNAs reproduced an EMT
phenotype. The cutoff threshold for an LWRM hit was 13.5 and
for the reporter intensity readout was 22.16 as described in the
‘‘Materials and Methods’’ section. Using this statistical cutoff, 42
of the candidate genes (10.5%) were classified as double-bin hits
(LWRM/VHM) (Fig. 2). Forty genes (10%) were validated as LWR-
only hits and 153 (38%) as VHM-only hits. These included 14
targets that scored 2/4 for both LWRM and VHM, but were not
from the same duplex and thus were classified as single-bin hits.
Further, five of nine targets that were originally scored as NC in
the primary screen but included due to being key mediators of
kinase inhibitor activity were scored as VHM (2/4 duplexes). This
included two targets that additionally scored 2/4 for LWRM, but
as only 1 duplex was in common between the outputs they were
classified as single-bin hits. One hundred seventy-nine initial hits
failed to validate as they scored £ 1/4 across all bin classes
(double bin, LWRM only, and VHM only).
Data Mining of Hits
To gain more information about the signaling and connectivity of
the 221 validated targets, we performed enrichment analysis using
GO process as the search term and identified cellular component
disassembly, protein complex disassembly, and regulation of fibro-
blast proliferation among the most significant processes (Table 5).
There were 11 genes in common between cellular component dis-
assembly and protein complex disassembly.
LWRM/VHM double-bin hits, the highest priority bin in the
context of this EMT study, comprised 42 genes that were clas-
sified as high confidence following validation. These genes
were assessed against the Oncomine, publicly available cancer
expression profiling database (www.oncomine.org). Consistent
with the concept that evidence of EMT is an indicator of a more
aggressive cancer phenotype, five of the hits were
overexpressed (top 10%) in superficial bladder cancer
(30 samples) compared with infiltrating (muscle in-
vasive) bladder urothelial carcinoma (10 samples) (P
value of 0.01) in a microarray analysis of 40 bladder
tumors.8
Validated genes were also associated with clinical
outcomes in other cancer types. For example, 43%
(18/42) of validated genes were associated with a
clinical outcome in breast cancer datasets. Four genes
were among the top 1% of genes with copy number
loss associated with poor survival in mucinuous
breast carcinoma,9 while 14 of the validated genes
(including 2 genes from the mucinous breast cancer
analysis) were included in the top 10% of genes with
copy number loss associated with metastatic events
and recurrence at 5 and 3 years in invasive breast
carcinoma.10
DISCUSSION
For EMT reporter regulation, we focused on the vimentin/dsRed
channel after E-cad/EGFP intensity proved to be too low to give a robust
differential reading. It has previously been established that the parental
TSU-Pr1 cell line does not express E-cadherin mRNA11 and that the
E-cadherin promoter is inactive in this cell line.12 Despite TSU-Pr1-
B1 cells exhibiting more epithelial characteristics than the paren-
tal TSU-Pr1 (morphologically and at the molecular level),13 this
Fig. 3. miR screen overview. Representative images of cells treated with miR-30c
mimic and miR-30c inhibitor at 72 h post-transfection. miR-30c-inhibitor-treated
cells display an elongated phenotype with an LWRM z-score of 4.79 and a VHM
z-score of 3.04, while there was no morphological change in miR-30c-mimic-treated
cells compared with mock (binned as no change). Scale bar = 100 mM. Images are a
merge of CMFDA (green) and dsRED (red) channels.
Table 3. miR Screen Overview
Binning Class
Number of Hits
(z-score ‡2 or £- 2)
miRNA mimic screen
LRWM/VHM 22
LWRM only 51
VHM only 122
NC 698
LC 346
miRNA inhibitor screen
LRWM/VHM 3
LWRM only 47
VHM only 72
LWRE only 18
NC 1080
LC 5
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was not sufficient to induce robust levels of E-cadherin expression.
Morphological change is another parameter associated with EMT,
with elongated fibroblastic shape being associated with mesen-
chymal phenotype and more cuboidal shape associated with the
epithelial state. Thus, a cell shape analysis was included in the
screen to create an integrated epithelial/mesenchymal assay.
In this multiparameter assay, siRNA
against SEMA3Awas used as the positive
control for the morphological-change
parameter. It was selected following
screening of a panel of potential LWR-
positive control siRNAs (Supplementary
Table S2) during assay development as it
demonstrated the highest z-score (and a
%CV of 16%) for LWR readout. SEMA3A
is an axon repulsion factor and has been
shown to reduce the migration and in-
vasive behavior of breast cancer MDA-
MB-231 cells14 and inhibited vimentin
expression during reversion of EMT in
pancreatic neuroendocrine tumors mice
model.15 Thus, SEMA3A is a negative
regulator of EMT.
The primary siRNA screen generated
a hit rate of 17% using a robust z-score
cutoff of ‡ 2. This relatively high hit
rate was attributed to the broad and
complex binning system used in this
multiparameter assay. Most primary
RNAi screens have a hit rate set at
around 2%–3%16–18 to enable priori-
tization of the most robust hits. We
used several approaches to refine our
hit list, including increasing the z-
score cutoff stringency and overlaying
miRNA screen target prediction genes
and kinases targeted by compounds in
a kinase inhibitor screen. Consistent
with practice in the facility in which the screen was performed, the
top 400 targets proceeded to validation.
The number of verified high-confidence hits in genome-wide
screens relies on the chosen statistical stringency and the assay type.19
Setting our high-confidence validation as those targets for which at
least 2 of the 4 individual siRNAs scored in the assay, we had a vali-
dation rate of 58.5%. Datamining with other cancer-related expression
profiles supports the validity of this assay in identifying genes involved
in maintaining epithelial phenotype.
Analysis of validated siRNA gene targets using gene ontology
identified fibroblast (mesenchymal cell) proliferation, prostate acinar
morphogenesis, and ERK1/2 signaling processes as enriched (Table 5).
In the prostate, terminally differentiated epithelia cells can undergo
EMT when regeneration is stimulated and such plasticity has been
associated with prostatic disease.20 In addition, ERK1/2 activity has
previously been established to regulate EMT in a number of cell types,
including prostate.21–23
Using the miRNA inhibitor library, we have identified miR-30c.
Inhibition of miR-30c scored LWRM (z-score 4.79) and VHM (z-score
3.04) but overexpression scored NC. This is consistent with the es-
tablished role for miR-30 family members in the regulation of EMT. In
Table 4. Compound Screen Overview
Binning Class
Number of Hits
(z-score ‡ 2 or £ -2)
LWRM and VHM 5
VHM 6
LWRM 11
LWRE 3
NC 60
LC 46
Fig. 4. Compound screen overview. The concentration response graph profile of SB59088, a
compound that targets B-RAF and one of the compounds that was binned as LWRE. The line
represents the dose–response curve. The y-axis represents the normalized values against the
specific controls for each parameter: for object count and object count per field, this is relative to
DMSO-only treatment wells; for the shape parameter, this is relative to siSEMA3A; and for total
intensity of reporter, this is relative to siCDH22. LWRE, length width ratio epithelial.
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human fetal pancreatic epithelial cells, depletion of miR-30 family of
miRNAs, including miR-30c, using antagomiRs resulted in the cells
transitioning to a mesenchymal phenotype.24 In human renal cell
carcinoma cells, miR-30c directly targeted EMT-promoting tran-
scription factor SLUG (SNAI2) and reduced E-cadherin to maintain an
epithelial phenotype.25 Similarly, miR-30c has been shown to inhibit
breast cancer cell chemoresistance (a feature also associated with
EMT26) by direct targeting of EMT-promoting actin-binding protein
twinfilin.27 Thus, miR-30c is a key inhibitor of EMT that was detected
using our HSC approach.
The screening of the small-molecule kinase inhibitor library served
as an adjunct to targeting protein kinases using siRNA. Potent inhibitor
of total BRAF SB59088528 was binned as LWRE based on graph profile
(Fig. 4B). In contrast, BRAFV600E-mutant-selective inhibitor PLX472029
scored LWRM/VHM based on its graph profile (data not shown). These
ambiguous results may be due to the nature of kinase inhibitors, which
often have multiple targets and different mechanisms of actions. In
thyroid cancer, BRAF has been shown to promote EMT, migration, and
invasion and invasion through TGFb andMEK-ERK signaling.30 This is
consistent with themore epithelial phenotype observed upon inhibiting
this kinase in the TSU-Pr1-B1 screen. These cells do not have the
BRAFV600E mutation; thus, it is likely that the more mesenchymal
phenotype induced by PLX4720 is due to an ‘‘off-target’’ effect despite
the reported specificity of this compound.
We present to the metastasis community a robust multiparametric
assay incorporatingmultiple levels of evidence to systematically define
regulators of EMT. The screen successfully identified known molecular
mediators of this plasticity program and provides an exceptional re-
source to explore the role of novel pathways.We are currently pursuing
leads generated in this screen in additional
cell and animal models to define the role of
these genes in the regulation of tumor cell
plasticity and metastasis.
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Abbreviations Used
CFMDA¼ 5-chloromethylfluorescein diacetate
CV¼ coefficient of variation
DAPI¼ 40 ,6-diamidino-2-phenylindole
DMEM¼Dulbecco-modified Eagle’s medium
EMT¼ epithelial-to-mesenchymal transition
FBS¼ fetal bovine serum
HCS¼ high-content screening
LWR¼ length width ratio
LWRE¼ length width ratio epithelial
LWRM¼ length width ratio mesenchymal
MET¼mesenchymal-to-epithelial transition
NC¼ no change
PBS¼ phosphate-buffered saline
VHE¼ vimentin promoter dsRED reporter activity associated
with increased epithelial-like properties
VHM¼ vimentin promoter dsRED reporter activity associated
with increased mesenchymal-like properties
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